Life Sciences Archive » May, 2023

Life Sciences - May, 2023

350 articles

• Abbott Says Ex-Nutrition Scientist Is Peddling Trade Secrets
• J&J Defends Talc Powder As 1st Post-Spinoff Trial Begins
• Mallinckrodt Can't Get Out Of Manhattan Project Waste Suit
• FDA Cracks Down On Illegal Sales Of Disposable E-Cigs
• Genentech Urges End To 'Threadbare' 401(k) Fees Suit
• Crowell & Moring Barred From Humana Case, Walgreens Says
• NC Manufacturer To Disband Amid Mountain Of Benzene Suits
• Why Fed. Circ. Should Explain Treatment Of Prior Art Ranges
• Stryker Loses Challenges To OsteoMed Patents At PTAB
• Neurosurgeon Says Partner In Med Tech Startup Hid Fraud
• A Watershed Moment For Microbiome-Based Therapy
• Nixon Peabody Taps Longtime Partner As Albany Office Head
• Legal Pitfalls To Watch For When Advertising Psychedelics
• Bayer Calls Whistleblower's Ex-Attys' Fee Bids Excessive
• Ex-FBI Trainee's Friend Liable In Stolen Stock Tips Suit
• Teva's Drug IP Deal With Gilead Not Pay To Delay, Jurors Hear
• Acthar Buyers Still Want Class Treatment In Antitrust Suit
• US Goes After Counterfeit Drug Labeling With New Sanctions
• Pfizer, Ex-Execs Say Trade Secrets Row Close To Being Settled
• Alnylam Widens Vaccine IP Litigation Against Pfizer, Moderna
• Real Estate Rumors: Popular Bank, Nuveen, Madison Capital
• Former FDA Officials Say Fosamax Claims Aren't Barred
• Elizabeth Holmes Begins 11-Year Prison Sentence In Texas
• Trending At The PTAB: IPR Estoppel After Ironburg
• Takeaways From New Fla. Pharmacy Benefit Manager Rules
• Federal Restrictions On Phthalates Are Long Overdue
• Suboxone Buyers Fight Late Dismissal Bid In Antitrust Case
• Amarin Legal Head Earned $2.6M Package In '22
• LabMD Agrees To Arbitrate Malpractice, Fraud Claims
• J&J Says New Ch. 11 Would Be Largest Settlement In History
• Justices Pass On Ex-Shkreli Attorney's Restitution Appeal
• 2 Firms Guide Anew Medical's $94M SPAC Merger
• 2nd Circ. Upholds Sackler Releases In Purdue Ch. 11 Plan
• Lilly To Pay $13M, Cap Insulin Cost In Deal Worth Up To $500M
• Court Temporarily Blocks SC Abortion Ban
• Evidence Should Shred Glycine Evasion Ruling, Importers Say
• Judge Won't Sink FCA Suit Over Medical Kickback Scheme
• Investor Activist Campaigns Heat Up Just In Time For Summer
• Ex-Fed. Circ. Chief Backs Another Patent Eligibility Case
• Fed. Circ. Backs ITC In Surgical Stapler IP Row
• DEA Targets Opioid Distributor Over 'Egregious Failures'
• Looking For Plausibility In FTC's Amgen Merger Challenge
• TCPA Protects Cellphone Users, Michigan Panel Rules
• Some Client Speculations On AI And The Law Firm Biz Model
• FDA Warns Cos. Of Potential Vape Product Violations
• UK Litigation Roundup: Here's What You Missed In London
• Chevron Deference In Limelight As DeSantis Joins 2024 Race
• SC's 6-Week Abortion Ban Violates Privacy, Challengers Say
• Amentum Says Exercise Company Atty Intimidated Witness
• PTAB Invalidates Patent Claims For Pelvis Joint Treatment
• Johnson & Johnson Settles 161 Hernia Mesh Suits In Ga.
• Illumina Shareholders Oust Board Chair Amid Icahn Battle
• RI Sues 3M And DuPont Over PFAS Contamination
• Judge Lets Gout Drug Antitrust Suit Move Forward
• Shkreli Cos. Bankruptcy Illustrates Novel Subchapter V Trend
• Insurer Says No Coverage For $100M Lab Theft Dispute
• Gilead, Teva Ink 11th-Hour HIV Antitrust Deal With Pharmacies
• 3 Firms Lead Medtronic's $730M Buy Of Insulin Patch Maker
• Teva Says Feds Can't Bolster FCA Suit With Advisory Rulings
• Jurors Weren't Barred Over Race, Gilead Antitrust Judge Says
• BALCA Says FAQ Can't Be Used To Deny Foreign Worker App
• 8th Circ. Sends 'Non-Drowsy' Walmart Suit Back To Fed. Court
• Judge Lets Walgreens Try To Shift Some Overbilling Blame
• LegitScript Can't Pause Blacklist Suit, Court Told
• On Deck In JPML: FTX, Cheer Abuse, T-Mobile
• PTAB Axes 5 Patents Over Owner's 'Egregious Abuse'
• 3rd Circ. Urged To Revive Fosamax MDL
• Merck's $10.8B Calif. Biotech Buy Goes Unchallenged By FTC
• Fed. Circ. Splits On When Exactly A Catheter Was Invented
• Boston Scientific Downsizes Stent Deal Under FTC Pressure
• USPTO Wants Feedback On How To Curb Counterfeit Goods
• Swedish Rare Disease Pharma Biz Ends Takeover Talks
• Glaxo Gets Second Wind In Inhaler TM Revival Bid
• Janssen Prevails In Patent Battle With Mylan Over Generics
• Monsanto Wins Roundup Trial Brought By Gardener
• HIV Drug Antitrust Trial 'Leaving The Station,' Judge Says
• DOJ, Drug Buyers Rip Teva's Criminal Probe Doc Bid In MDL
• Delaware Jury Rejects Suit Alleging Overpayments To Rite Aid
• 4 Firms Steer Canadian Automation Firm's $275M US IPO Plan
• Dollar General Escapes Pain Patch Packaging Class Action
• Apple Says Masimo Can't Revive Biz Trade Secrets In IP Row
• Philips Owes $2.5M Treble Damages After IP Trial, Rival Says
• Bayer Beats Consumers' 'Vague' Benzene Contamination Suit
• Nurse Targets Chicago Hospitals Over Biometric Cabinets
• Janssen And Amgen Settle Patent Row Over Stelara Biosimilar
• Purdue Approved For OTC Biz Sale As Ch. 11 Case Drags On
• Biotech Co. Says Red Cross Plainly Violated Antitrust Law
• Walgreens Nears Settlement In Theranos MDL
• Ga. Judge Ends Most Claims In Ermi Whistleblower Suit
• A Lawyer's Guide To Approaching Digital Assets In Discovery
• In-House Labor Veteran Joins Seyfarth As Partner In NC
• Sandoz Sues To Invalidate Prostate Cancer Drug Patent
• What IP Attys Should Know About Enablement After Amgen
• Teva Accused Of Asthma Inhaler Antitrust Scheme
• Economic Claims Tossed From Abbott Formula MDL
• High Court's Ethics Statement Places Justices Above The Law
• DOJ Says Not To Toss FCA Case Against Hospital System
• Justices Won't Eye Rulings Over Hirshfeld PTAB Decisions
• Pharma Co. Hid Nonhuman Primate Imports, New Suit Says
• Walgreens Says Crowell 'Betrayal' Led To $642M Humana Win
• High Court Amgen Patent Ruling Promotes Medical Innovation
• Catching Up With Delaware's Chancery Court
• AstraZeneca Sales Reps Fight To Keep Pay Bias Suit Alive
• CureVac Lobs Infringement Counterclaims At BioNTech, Pfizer
• Ex-Amgen Exec's Startup Gets PTAB To Review Amgen Patent
• Walgreens Judge Warns SF $230M Opioid Deal No Candy Jar
• Monsanto Rep 'Always' Considered Roundup Safe, Jury Told
• Mylan Beats Most Claims In Investor Suit Over W.Va. Plant
• Bayer Investors Land Class Cert. Over Roundup Litigation
• Del. Court Rejects Tricida's Ch. 11 Plan, Citing Unfair Opt-Outs
• 1st Circ. Won't Revive J&J Hip Implant False Claims Act Suit
• White House Looks To Scrap CBP Worker's Vax Mandate Case
• Jury Clears Miami Drug Trial Co.'s CEO Of Fraud Charges
• Harvard Fights Vizgen's Claims In Spatial Imaging Patent Fight
• Dow Cancer Suits To Stay Separate Over Workers' Differences
• Time For Law Schools To Rethink Unsung Role Of Adjuncts
• IP Litigator Leaves Stroock For Venable In NY After 1 Year
• Fieldfisher Hires Cybersecurity Pro From Shoosmiths
• UK Litigation Roundup: Here's What You Missed In London
• Justices Clamp Down On Broad Patents In Amgen Decision
• Del. Court Trims Biotech Investors' Stock Transfer Suit
• Takeda Rejects $480M AbbVie Claim In Del. Drug Shortage Suit
• FDA Says More Than 250 E-Cig Products Can't Be Sold In US
• Takeaways From FTC's Challenge Of Amgen Deal
• Mich. Health System To Pay $800K To End Meal Break Suit
• Lab Can't Trim PerkinElmer's $6.3M COVID-19 Gear Suit
• DEA Affirms Denial Of Doctor's Bid To Reschedule Psilocybin
• Defending The Religious And Spiritual Use Of Psychedelics
• Prior Cases Bar Janssen Kickback FCA Claims, Judge Told
• Judge Denies Horse Assoc.'s Injunction Bid Pending Appeal
• Duo Says USCIS Keeps 'Unnecessary' $85 Biometric Fees
• What The Justices' Questions Signify For FCA Compliance
• Deals Rumor Mill: Manchester U, Ottawa Senators, Maravai
• Sanofi Wins Patent Enablement Fight At Supreme Court
• The First States Jumping Into Regulating Psychedelics
• 5th Circ. Needles FDA On Its Abortion Pill Approval Process
• Juul And Altria To Pay $60.5M In Minn. Youth Vaping Deal
• Chancery OKs Deal, $1.35M Atty Fee To End Drug Trial Suit
• 6th Circ. Won't Rethink FCA Hiring Case Decision
• Synthego Gets PTAB To Ax 2 Agilent CRISPR Patents
• FTC Adds CVS Unit, Another Group Purchaser To PBM Probe
• Ex-Immunomedics CFO Cops To Giving Stock Tip To Girlfriend
• CureVac Gets Pfizer COVID Vax Patent Fight Moved To Va.
• Elizabeth Holmes Gets New May 30 Self-Surrender Date
• Judge Won't Free Glove Maker From Forced Labor Suit, Yet
• Pa. Doctor, Pharmacy Sued For Over-Prescribing Medicines
• Tips For In-House Legal Leaders In A Challenging Economy
• Baker Botts Grows Singapore Office To 7-Lawyer Team
• Walgreens To Pay SF $230M After Landmark Opioid Trial Loss
• 6 Firms Build Canadian Biotech SPAC Merger
• 2nd Circ. Denies AstraZeneca Investors New Shot At Vax Suit
• Holmes Ordered To Prison, Hit With $452M Restitution
• NC Republicans Jettison Governor's Veto On Abortion Limits
• Tech, Drug Cos. Back Ban On AI As Inventor On Patents
• ITC To Partly Review Apple Watch Patent Decision
• Jazz Ducks BCBS Claims But Not Xyrem Class Cert.
• J&J's $8.9B Talc Deal Includes $400M To 6 States
• Tips For Drafting Paragraph IV Notice Letters
• NJ Panel Won't Revive Investor Suit Over Medical Co. IPO
• Proskauer Must Face Cut-And-Paste Malpractice Suit
• Nossaman Adds 2 Health Care Partners In Calif. Capital
• J&J Talc Unit Can Pursue Ch. 11 Plan During Dismissal Fight
• Psychedelics Companies Face Quandary In Protecting IP
• Crowell Nabs IP Atty Team With Disruptive Tech Experience
• FTC Challenges $28B Amgen-Horizon Therapeutics Merger
• Qualms With Abortion Can't Crush Pill Access, 5th Circ. Told
• What's Next For Patent Eligibility After Latest Denials?
• 2nd Circ. Backs Denial Of Fees For Former PixarBio Attys
• 9th Circ. Revives San Francisco Workers' Vax Mandate Fight
• Gilead HIV Drug Fight Begins Rare Summary Jury Trial
• Scorpion Venom Drug Biz Hit With SEC Fraud Suit
• Judge Affirms $490M FCA Verdict Against Medical Distributor
• Natera Nets $19M Verdict In Cancer Test Patent Case
• The Clinic Fighting For Patients' Right To Try Mushrooms
• Saudi Pharma Co. Eyes $336M IPO Steered By 4 Firms
• Justices Won't Take Up $39M Monsanto Cy Pres Settlement
• Judge OKs Ga. Manufacturer's Plan To Stop PFAS Pollution
• Catching Up With Delaware's Chancery Court
• A Fresh Look At The Jury Data In Waco Patent Trials
• Ravgen's Prenatal Test Patent Win Boosted To $372M
• Conn. Lab Fights Insurer Over $2.4M Tropical Storm Loss
• Firms To Seek $2M For Pharma Suit Settlement In Del.
• Pension Fund Wants To Lead $10B Amgen Tax Dispute
• What Associates Need To Know Before Switching Law Firms
• High Court Refuses To Hear 'Skinny Label' Drug Patent Case
• Insys Trustee Says Court Should Halt Insurance Coverage Suit
• Wash. Fish Health Co. Broke Deal, Chilean Distributor Says
• Gardener Rests Roundup Case After Telling Of Cancer Pain
• Biotech Co. Wants Chubb Unit's $3M Fire Suit Tossed Again
• FTC Says Horse Association Bid For Injunction Will Likely Fail
• FDA Won't Approve 6,500 E-Cigs For US Market
• Moderna Fires Back At Rival's 'Baseless' Vaccine Patent Row
• How Fed. Circ. Is Applying Section 101 To Drug Patents
• Talc Victims Seek Right To Sue J&J Over Voided Funding Deal
• NephroSant Founder's Chancery Redaction Bid Is Rejected
• UK Litigation Roundup: Here's What You Missed In London
• Taxation With Representation: Gibson Dunn, Davis Polk
• A Case For Sharing Mediation Statements With Counterparties
• Companies Explore Costly Capital-Raising Ideas Amid Slump
• Altria's Vaping Claims Deal Could Spur Other Settlements
• Philips Inks $62M Deal Resolving FCPA Allegations From SEC
• SmileDirectClub Asks 9th Circ. To Seal Invisalign Co.'s Suit
• Senate Panel Approves Bipartisan PBM Overhaul
• Ohio Opioid Settlement Foundation Must Make Records Public
• DOJ Sanctioned In FCA Case Over Discovery Dispute
• Second Investor Rebels Against Aurinia Pharmaceutical Board
• Tackling Long-Tail Legacy Liability Risk: A Defendant's Toolkit
• Indivior Wants Class Tossed From Suboxone Antitrust Case
• Challenging Standing In Antitrust Class Actions: Injury-In-Fact
• Ex-IRS Officer Led $3M Pandemic Loan Scam, Feds Say
• NC Contractor Jilted Ohio Corp. On $15M Project, Suit Says
• Reupped Bill Pushes Review Of Outbound China Investments
• Astellas, Scientists Settle Stem Cell Patent Inventorship Fight
• Fortis Rips J&J's Bid To DQ Selendy Gay In Chancery Case
• What COVID Vaccines May Reveal About SEPs Amid Crisis
• Deals Rumor Mill: Saudi Aramco, Alibaba, Meta
• Del. Judge Says InterMune Doesn't Have To Indemnify Ex-CEO
• Lack Of HIV Drug Deal Before Trial Shocks Antitrust Judge
• Biotech Co. Facing Third Contempt Says It Misread Order
• LegitScript Renews Bid To Pause Price Check Blacklist Suit
• Jeb Bush-Led SPAC Fails To Find Merger Partner
• To Gets Vaccine Bundling Suit Tossed, Merck Points To GSK
• Roundup Cases Need To Move, Mo. High Court Hears
• Fed. Circ. Won't Review Dartmouth's Milk Vitamin Patent Loss
• Judge Greenlights Claim Over 'Extra Strength' Vitamin C
• SEC Says Medical Device Co. Duped Investor In $730K Deal
• FCA Chases 'Shrewder' Kickbacks As 50-Year Hunt Intensifies
• Investor Can't Undo $155M Lubricant Co. Acquisition, For Now
• Working From Home? Beware Insider Trading, Tipping Risks
• Fed. Circ. Won't Revive Vanda's Sleep Disorder Patent Claims
• Preparing For Legal Scrutiny Of Data Retention Policies
• FDA Panel Votes For OTC Birth Control Pill
• Altria Strikes $235M Deal To End Youth Vaping Claims
• Fujifilm To Buy Entegris Electronic Chemicals Biz For $700M
• Convicted 'Pharma Bro' Shkreli's Companies File For Ch. 11
• Biz Groups Again Push For Litigation Funding Disclosure Rule
• Eli Lilly Drug Rebate Damages Tripled To $183M
• Roundup Was Likely Cause Of Plaintiff's Cancer, Jury Hears
• Dow, PPG Can't Escape Punitives In Calif. Contamination Suit
• SF Schools Need $92M For Vaping Fix, Altria Jury Told
• FDA's 'Radical' Abortion Pill Stance Fails, 5th Circ. Told
• Treasury Blacklists 4th 'Chapito,' Cartel 'Super Lab' Head
• Proskauer Eyes Early Win In Copy-Paste Malpractice Suit
• Fed. Circ. Says PTAB Wrongly Sunk Sanofi Injector Pen Patent
• DEA Extends Telehealth Rule For Controlled Substances Rx
• Congress Must Reform PBMs To Lower The Cost Of Insulin
• 3rd Circ. Won't Revive J&J Investors' Arbitration Proposal Suit
• Niaspan Buyers Ask 3rd Circ. For Rehearing On Class Cert.
• Ga. City, Manufacturer Agree To Stop PFAS Pollution
• HHS Urges Court To Toss Texas Abortion Pill Suit
• Fed. Circ. Ruling Can Serve To Guide Patent Range Claims
• Ex-Allen & Overy IP Atty Joins Duane Morris In Silicon Valley
• FTC's Framework For Assessing Direct Selling Cos. Is Flawed
• 3rd Circ. Says J&J Talc Unit's Ch. 11 Should Proceed
• Jury Rejects Feds' Claims Gilead Infringed HIV Drug Patents
• Altria Fueled Juul Vaping Crisis, Harvard Prof. Testifies
• Pfizer Spinoff Sued By Former Vax Supplier
• FDA Hit With Suit Looking To Keep Abortion Drug Access
• Talc Co. Tells 3rd Circ. Ch. 11 Mandamus Writ Is Premature
• ITC Looking Into China, Taiwan Drug Device Imports
• PE Firms To Pay $4.25B For Baxter's BioPharma Solutions Biz
• Illumina Tells Shareholders Icahn Wrong About Selling Grail
• Paul Weiss' Veeraraghavan On Slew Of Health Care Deals
• Dope Seller Cops To Supplying Olympic Sprinter Before Tokyo
• Astellas, Aon Strike Deal In 401(k) Management Class Action
• Director Exits Cancer Drug Co. Following Farallon Pressure
• Attorneys Should Have An Ethical Duty To Advance DEI
• Catching Up With Delaware's Chancery Court
• Del. Justices Order Chancery Review Of Yanked Stock Grants
• Walgreens To Face Theranos MDL, Escapes Punitive Claims
• Joint Juice Maker Rips Class Attys' 'Overstated' $8.3M Fee Bid
• 3rd Circ. Upholds Class Cert. Denial In Niaspan MDL
• Roundup User's Lymphoma Journey 'Not The Norm,' Jury Told
• 8th Circ. Upholds Conviction Of Ex-Monsanto Scientist
• Stryker Settles Faulty Spinal Device Claims Days Before Trial
• Judge Won't Rethink Injunction In Idaho Abortion Law Suit
• Kenvue's IPO Offers Glimmer Of Hope During Bleak Times
• Drug Co. Wants Houston Judge To Halt Opioid MDL Discovery
• FDA Alum And Regulatory Pro Joins Walmart Legal Team
• Ohio Hospital Wants Nurses' Unpaid OT Suit Nixed
• New Considerations In Med Device Cybersecurity Compliance
• Texas Panel Won't Re-Freeze Gilead Medicaid Fraud Suit
• Fed. Circ. Vacates PTAB Ax Of Guardant DNA Test Patent
• NC Town Sues 30 Cos. Alleging 'Forever Chemicals' Pollution
• Geron Investors Report No Objections To $1.35M Atty Fee Bid
• Health Hires: Blank Rome, Husch Blackwell
• Titan Of The Plaintiffs Bar: Motley Rice's Joe Rice
• Data-Driven Insights Are Key To Attracting Today's Clients
• Taxation With Representation: Wachtell, Kirkland, Fried
• UK Litigation Roundup: Here's What You Missed In London
• Apple, Masimo Denied JMOL Wins In $1.85B Watch IP Row
• NC's 12-Week Abortion Ban Passes Both State Chambers
• 4th Circ. Tests Walgreens' Bid To Skip Medicaid Fraud Liability
• 11th Circ. Urged To Rethink Nix Of $8M Supplement Deal
• BioTech Co. Must Prove It Didn't Flout Court Order In SEC Suit
• Cooley, Davis Polk Steer Biotech Firm's Upsized $540M IPO
• Lannett Seeking Fast Run Through $600M Reorg
• Full Fed. Circ. Won't Rethink Decision On Heart Drug IP
• Biopharm Co. Sued In Del. Over Consent Right Ban
• Federal Oversight Of AI In Healthcare Is Taking Shape
• Deals Rumor Mill: Pfizer, Subway, SoftBank
• Kroger Strikes $68M Deal To Avoid Trial In W.Va. Opioid Suit
• Buchanan Ingersoll Gets $700K In Fee Dispute With Ex-Client
• Altria Accused Of 'Pseudo Social Responsibility' At Trial
• Ex-FDA Officials Back Feds In Abortion Pill Fight At 5th Circ.
• Judge Cuts Disgorgement Ex-Atty Owes SEC In Fraud Case
• North Carolina House Approves 12-Week Abortion Ban
• Dismissal Motion Hearing Set For June In J&J Talc Ch. 11
• 4 Firms Lead Regentis Biomaterials In $95M SPAC Merger
• W. Va. Abortion Drug Law Fight Can Continue, Judge Rules
• Stryker Hires Counsel To Launch New Internal FCPA Probe
• GSA Botched Bid Review In $238M Storage Row, GAO Says
• Ohio Businessman Admits Role In $24M Health Fraud
• Ghosting In BigLaw: Why Better Feedback Habits Are Needed
• 'Extortion' Charge Roils FCA Bar As Kickback Suits Surge
• Tenn. Eye Center To Pay $17M To Settle Kickback Claims
• Ex-Juul COO Says He Was Fired After Raising Teen User Fears
• Wis. High Court Won't Force Hospital To Use Ivermectin
• Reject 'Carte Blanche' For Risky Opioid Sales, 4th Circ. Urged
• Biotech Co. Can't Ax Beefed Up IP Theft Claims Before Trial
• Stanford Urges High Court To Take 'Ideal' Patent Law Case
• Talc Claimants Ask 3rd Circ. To End J&J Unit's New Ch. 11
• Sandoz Drops Counterclaims After $39M Patent Trial Loss
• Essential Oils False Ad Suit Revived By 2nd Circ.
• DuPont To Buy Spectrum Plastics Group From AEA For $1.75B
• 1st Circ. Receptive To Reviving Rx Delivery Data Breach Suit
• NJ Jury Sides With J&J Unit In Pelvic Mesh Injury Suit
• Activist Investor Nominates 2 Candidates For Masimo Board
• Juul Investor Concedes Family's Vaping Concerns At Trial
• 'Momentous Day' As Justices Eye Chevron Deference Demise
• Humana, Aetna Say Calif. Law Bars Drugmaker's Fed. Court Bid
• Amazon Patent Evaluators Are Biased, Lawsuit Says
• NC Couple Drops 3M, Others From Asbestos Cancer Suit
• DC Circ. Asks What's Wrong With Endo-Impax Deal
• Drugmaker Lannett Strikes Deal On $511M Debt Restructure
• Judge Wary Of Economic Claims In Abbott Formula MDL
• Mistrial Declared In Masimo's $1.85B IP Fight Against Apple
• Biotech Investor Makes 2nd Push For $1.4M Deal Approval
• Biotech Co. To Face Amended Investor Suit Over COVID Test
• Chinese Carbon Cos. Dealt Back-To-Back Losses In Duty Row
• Arrayit Exec Denied New Trial In COVID Test Fraud Case
• Examining Chancery's Recent Openness To Caremark Claims
• Catching Up With Delaware's Chancery Court
• Brown Rudnick's NY Office Picks Up Drug Patent Pro
• Don't Let Gov't Read Law Into Obscurity, Arthrex Says
• NJ Appeals Panel Upholds Merck's $1.4B Cyber Coverage Win
• Law Needs A Balance Between Humanism And Formalism
• Titans Of The Plaintiffs Bar: Bleichmar Fonti's Name Partners
• Cooley-Led Biotech Firm Launches Plans For $350M IPO
• 9th Circ. Asked To Rethink Stem Cell Injury Coverage Ruling